Literature DB >> 23772636

DNA repair initiation induces expression of ribonucleotide reductase in human chronic lymphocytic leukemia cells.

Martha Rodriguez Sandoval1, Kumudha Balakrishnan, Rajyalakshmi Luthra, Michael Keating, Varsha Gandhi.   

Abstract

Mammalian ribonucleotide reductase (RR) is a heterodimer enzyme responsible for maintaining levels of deoxynucleotides needed for DNA replication. The M2 subunit of RR is known to increase in tandem with progression of cells into S phase, whereas the M1 subunit is expressed at steady-state. Since the expression level of the M2 subunit increases because the cells need deoxyribonucleoside triphosphates (dNTPs) for replication, it is logical to hypothesize that the same increase will be seen during DNA repair. To test this, we used chronic lymphocytic leukemia (CLL) cells, which are replicationally quiescent and have low endogenous levels of RR and dNTPs. Cyclophosphamide was selected as the DNA damaging agent because of its clinical use in the treatment of CLL. DNA repair, measured by [(3)H]thymidine incorporation after 4 h treatment with 4-hydroperoxycyclophosphamide, increased in a dose-dependent manner at 3, 10 and 50 μM. The induction of DNA repair concomitantly increased the mRNA and protein levels of M2 subunit (median 1.6-fold; range 0.9-5.3). Maximum induction occurred at 10 μM after 4 h and correlated with [(3)H]thymidine incorporation (p = 0.02). In contrast, no change was observed in mRNA or protein levels of M1 subunit. We conclude that RR is regulated not only during replication but also during DNA repair, and in both cases M2 subunit expression is increased.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23772636      PMCID: PMC4102412          DOI: 10.3109/10428194.2013.813497

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  46 in total

1.  UCN-01 (7-hydroxystaurosporine) inhibits DNA repair and increases cytotoxicity in normal lymphocytes and chronic lymphocytic leukemia lymphocytes.

Authors:  Takahiro Yamauchi; Michael J Keating; William Plunkett
Journal:  Mol Cancer Ther       Date:  2002-02       Impact factor: 6.261

2.  Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.

Authors:  S M O'Brien; H M Kantarjian; J Cortes; M Beran; C A Koller; F J Giles; S Lerner; M Keating
Journal:  J Clin Oncol       Date:  2001-03-01       Impact factor: 44.544

3.  Radiation stimulated incorporation of thymidine into the DNA of human lymphocytes.

Authors:  R G Evans; A Norman
Journal:  Nature       Date:  1968-02-03       Impact factor: 49.962

Review 4.  The contribution of homologous recombination in preserving genome integrity in mammalian cells.

Authors:  L H Thompson; D Schild
Journal:  Biochimie       Date:  1999 Jan-Feb       Impact factor: 4.079

5.  Ribonucleotide reductase from calf thymus. Separation of the enzyme into two nonidentical subunits, proteins M1 and M2.

Authors:  L Thelander; S Eriksson; M Akerman
Journal:  J Biol Chem       Date:  1980-08-10       Impact factor: 5.157

6.  Health-related quality of life in younger patients with chronic lymphocytic leukemia treated with fludarabine plus cyclophosphamide or fludarabine alone for first-line therapy: a study by the German CLL Study Group.

Authors:  Barbara F Eichhorst; Raymonde Busch; Tanja Obwandner; Ingrid Kuhn-Hallek; Peter Herschbach; Michael Hallek
Journal:  J Clin Oncol       Date:  2007-03-26       Impact factor: 44.544

Review 7.  Eukaryotic DNA mismatch repair.

Authors:  R D Kolodner; G T Marsischky
Journal:  Curr Opin Genet Dev       Date:  1999-02       Impact factor: 5.578

8.  DNA repair initiated in chronic lymphocytic leukemia lymphocytes by 4-hydroperoxycyclophosphamide is inhibited by fludarabine and clofarabine.

Authors:  T Yamauchi; B J Nowak; M J Keating; W Plunkett
Journal:  Clin Cancer Res       Date:  2001-11       Impact factor: 12.531

9.  Phase III trial of fludarabine plus cyclophosphamide compared with fludarabine for patients with previously untreated chronic lymphocytic leukemia: US Intergroup Trial E2997.

Authors:  Ian W Flinn; Donna S Neuberg; Michael R Grever; Gordon W Dewald; John M Bennett; Elisabeth M Paietta; Mohamad A Hussein; Frederick R Appelbaum; Richard A Larson; Dennis F Moore; Martin S Tallman
Journal:  J Clin Oncol       Date:  2007-02-05       Impact factor: 44.544

10.  Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): a randomised controlled trial.

Authors:  D Catovsky; S Richards; E Matutes; D Oscier; Mjs Dyer; R F Bezares; A R Pettitt; T Hamblin; D W Milligan; J A Child; M S Hamilton; C E Dearden; A G Smith; A G Bosanquet; Z Davis; V Brito-Babapulle; M Else; R Wade; P Hillmen
Journal:  Lancet       Date:  2007-07-21       Impact factor: 79.321

View more
  2 in total

1.  Phase I and extension study of clofarabine plus cyclophosphamide in patients with relapsed/refractory acute lymphoblastic leukemia.

Authors:  Stefan Faderl; Kumudha Balakrishnan; Deborah A Thomas; Farhad Ravandi; Gautam Borthakur; Jan Burger; Alessandra Ferrajoli; Jorge Cortes; Susan O'Brien; Tapan Kadia; Jennie Feliu; William Plunkett; Varsha Gandhi; Hagop M Kantarjian
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2013-12-17

2.  Radiopharmaceuticals for Relapsed or Refractory Leukemias.

Authors:  Charles A Kunos; Jacek Capala; Susan Percy Ivy
Journal:  Front Oncol       Date:  2019-02-25       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.